Leukemia :: New hope for patients with chronic lymphocytic leukemia
Patients treated with lenalidomide for relapsed chronic lymphocytic leukemia or disease that no longer responds to chemotherapy have experienced a major response to therapy, according to a phase II study conducted by Asher Chanan-Khan, M.D., Department of Medicine, Roswell Park Cancer Institute. The results are published in the December 1 issue of the Journal of Clinical Oncology.